Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from

Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did.

Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it.

semaglutide, monoisotopic mass near 4113.6 Da, 27 weeks of my own notes, and 4 lots from 4 suppliers with a purity figure on each. That is the whole basis of what follows.

What I want checked is the reasoning I have built on top of it, not the figures themselves.

A request rather than an answer: could whoever has the primary source for Semaglutide half-life post it? I have seen the claim three times this month and each version had lost a qualifier.

I read the opening post twice before replying, because I had assumed the opposite.

The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.

If the premise is wrong, everything after it is decoration.

The opening post answers the question as asked. The question underneath it is different.

Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.

Correct me on the arithmetic if it is wrong; I would rather know.

Worth separating two things that the opening post runs together.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

The general case is well covered; this is the awkward specific one.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

I had read the opposite somewhere and cannot now find where, which tells me something.

Post #5 is right about the mechanism and I think understates the practical bit.

Renal outcomes moved this compound out of the metabolic-only conversation. FLOW reported on kidney endpoints in people with type 2 diabetes and chronic kidney disease, which is a narrower population than the discussion here usually assumes.

I would rather post the uncertainty than round it away.

Where I part company with post #5, and it is a narrow parting.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

A guess, clearly labelled as one.

Post #9 is the version of this I will quote in future. One addition.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

I would not lead a decision with this, but I would not ignore it either.

The failure mode on Semaglutide half-life is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.

That is the practical version. The rigorous version is longer and says the same thing.

Post #10 answers the question as asked. The question underneath it is different.

Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.

The mechanism is plausible, which is not the same as established.

Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.